» Articles » PMID: 38863707

Structural and Functional Characterization of IgG- and Non-IgG-based T-cell-engaging Bispecific Antibodies

Overview
Journal Front Immunol
Date 2024 Jun 12
PMID 38863707
Authors
Affiliations
Soon will be listed here.
Abstract

Bispecific T-cell-engaging antibodies are a growing class of therapeutics with numerous molecules being tested in clinical trials and, currently, seven of them have received market approval. They are structurally complex and function as adaptors to redirect the cytotoxicity of T cells to kill tumor cells. T-cell-engaging bispecific antibodies can be generally divided into two categories: IgG/IgG-like and non-IgG-like formats. Different formats may have different intrinsic potencies and physiochemical properties, and comprehensive studies are needed to gain a better understanding of how the differences in formats impact on structural and functional characteristics. In this study, we designed and generated bispecific T-cell-engaging antibodies with IgG-like (DVD-Ig) and non-IgG (BiTE) formats. Both target the same pair of antigens (EGFR and CD3) to minimize the possible influence of targets on functional characterization. We performed a side-by-side comparison to assess differences in the physiochemical and biological properties of these two bispecific T-cell-engaging antibodies using a variety of breast and ovarian cancer cell-based functional assays to delineate the structural-functional relationships and anti-tumor activities/potency. We found that the Fc portion of T-cell-engaging bispecific antibodies can significantly impact antigen binding activity, potency, and stability in addition to eliciting different mechanisms of action that contribute the killing of cancer cells.

References
1.
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A . Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007; 25(11):1290-7. DOI: 10.1038/nbt1345. View

2.
Choi B, Yu X, Castano A, Bouffard A, Schmidts A, Larson R . CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019; 37(9):1049-1058. DOI: 10.1038/s41587-019-0192-1. View

3.
Singh K, Hotchkiss K, Mohan A, Reedy J, Sampson J, Khasraw M . For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer. 2021; 9(11). PMC: 8603282. DOI: 10.1136/jitc-2021-003679. View

4.
Huehls A, Coupet T, Sentman C . Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2014; 93(3):290-6. PMC: 4445461. DOI: 10.1038/icb.2014.93. View

5.
Nakai K, Hung M, Yamaguchi H . A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8):1609-23. PMC: 5004067. View